All Outputs (7)

Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected (2021)
Journal Article

Tumour microenvironments are hallmarked in many cancer types. In haematological malignancies, bone marrow (BM) mesenchymal stromal cells (MSC) protect malignant cells from drug-induced cytotoxicity. However, less is known about malignant impact on su... Read More about Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected.

Shedding smart light on the effectiveness of chemotherapy: using Raman spectroscopy and machine learning to differentiate the effects of Cytarabine toxicity and crosstalk of leukaemic and bone marrow stromal cells (2021)
Presentation / Conference Contribution

Mesenchymal stromal cells (MSC) protect leukaemic cells from drug-induced toxicity within the bone marrow niche, with increasing evidence of leukaemic impact on supportive stroma. The nucleoside analogue, cytarabine (ara-C), is a front-line agent for... Read More about Shedding smart light on the effectiveness of chemotherapy: using Raman spectroscopy and machine learning to differentiate the effects of Cytarabine toxicity and crosstalk of leukaemic and bone marrow stromal cells.

Interaction between leukaemic cells and the bone marrow stroma (2020)
Thesis

Mesenchymal stromal cells (MSC) enhance growth and protect leukaemic cells from drug-induced toxicity in the bone marrow microenvironment (BMM), however, these interactions are not fully understood and less is known about the impact of leukaemic cell... Read More about Interaction between leukaemic cells and the bone marrow stroma.

Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease (2019)
Presentation / Conference Contribution

Resistance to therapy remains one of the greatest challenges in the management of the blood and bone marrow (BM) disorder, acute myeloid leukaemia (AML). This study aimed to investigate how leukaemic and BM stromal cells contribute to altered chemo-s... Read More about Leukaemic and bone marrow stromal cells alter cytarabine genotoxicity and cytotoxicity in favour of disease.

Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML). (2019)
Presentation / Conference Contribution

Mesenchymal stromal cells (MSC) are known to protect leukemic cells from drug-induced toxicity within the bone marrow (BM) niche, however, less is known about leukemic impact on supportive MSC. The nucleoside-analogue, cytarabine (Ara-C), is a front-... Read More about Influence of Bone Marrow Stromal and Leukemic Cells on Cytarabine Chemo-Toxicity in Acute Myeloid Leukemia (AML)..

Chemotherapy-induced genotoxic damage to bone marrow cells: Long-term implications (2018)
Journal Article

© The Author(s) 2018. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. Mesenchymal stem/stromal cells (MSCs) within the bone marrow (BM) are vitally important in forming the micro-environment supporting haematop... Read More about Chemotherapy-induced genotoxic damage to bone marrow cells: Long-term implications.

Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor (2017)
Presentation / Conference Contribution

This study aimed to develop a 2D leukaemia-stroma model of the bone marrow for analysis of stromal-mediated chemo-protection; known to contribute to chemotherapy resistance. The model must facilitate integration of a bioluminescent biosensor HA1 for... Read More about Development of a 2D leukaemia-stroma model for analyses of chemo-toxicity protection using a novel bacterial bioluminescent biosensor.